Citius Oncology Inc (Nasdaq: CTOR), a US-based specialty biopharmaceutical company, announced its financial results for the fiscal full year ended 30 September 2024 on Friday.
The company reported R&D expenses at USD4.9m for the full year ended 30 September 2024 compared to USD4.2m for the year-ended 30 September 2023.
The firm posted G&A expenses at USD8.1m for the full year ended 30 September 2024, compared to USD5.9m for the same period in 2023.
The company reported stock-based compensation expense at USD7.5m for the full year ended 30 September 2024, compared to USD2m for the full year ended 30 September, 2023.
The firm reported net loss at USD21.1m or USD0.31 per share for the full year ended 30 September 2024, compared to a net loss of USD12.7m or USD0.19 per share for the full year ended 30 September 2023.
Duality Biologics reveals B7H4 ADC milestone achievement and license exercise by BeiGene
Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial
Citius Oncology reports financial results for fiscal full year ended 30 September 2024
IDEAYA Biosciences enters license agreement with Jiangsu Hengrui Pharmaceuticals
TEVIMBRA approved in US for first-line gastric and gastroesophageal junction cancers
Hoth Therapeutics signs patent licence agreement with US Department of Veterans Affairs
Puma Biotechnology announces inclusion of NERLYNX in NCCN guidelines for cervical cancer treatment
CStone Pharmaceuticals submits clinical trial application in Australia for CS2009